35 recruiting. 35 Phase 2, 13 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Recruiting 35 |
| Phase 1 | 13 | Recruiting 13 |
| Phase 3 | 2 | Recruiting 2 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
| Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC) Neoadjuvant Therapy, Upfront radical cystectomy - Bladder Cancer | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 60 | 2026-07-10 | 2026-08-13 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC Intravesical Gemcitabine and Docetaxel - Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Recruiting | Michael A. O'Donnell | 174 | 2026-04-10 | 2026-04-17 |
| Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer Dutasteride (0.5mg) - Bladder Cancer | Phase 2 | Recruiting | Paul Toren | 95 | 2026-03-25 | 2026-03-30 |
| Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Systemic immunotherapy - Bladder Cancer, Liquid Biopsy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 53 | 2026-03-16 | 2026-05-26 |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) MK-3120, EV, Pembrolizumab - Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 55 | 2026-02-09 | 2026-10-02 |
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors EBNK-001 + IL-15 + Pembrolizumab - Cancer, Sarcoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 83 | 2026-02-01 | 2026-02-18 |
| A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) MK-3120 - Bladder Cancer, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 45 | 2025-12-09 | 2026-10-29 |
| Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT) - Bladder Cancer | Phase 2 | Recruiting | Changhai Hospital | 31 | 2025-12-08 | 2026-07-21 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Dato-DXd, Carboplatin, Cisplatin - Urothelial Cancer, Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 630 | 2025-09-26 | 2026-08-20 |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [18F]FAPI-74, [18F]FDG - Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-09-09 | 2026-10-29 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors CP-383 - Solid Tumor Malignancies, Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Tasca Therapeutics | 150 | 2025-08-27 | 2026-02-18 |
| Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery Comprehensive multimodal prehabilitation (CMMP) - Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa) | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 148 | 2025-08-14 | 2026-03-12 |
| Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) Gemcitabine, Cisplatin, Cemiplimab - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 2 | Recruiting | Columbia University | 36 | 2025-08-14 | 2025-09-02 |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT) - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 47 | 2025-03-31 | 2026-10-01 |
| Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer Intravenous ascorbic acid/vitamin C - Bladder Cancer | Phase 2 | Recruiting | University of Kansas Medical Center | 48 | 2025-01-16 | 2025-02-20 |
| Telehealth Intervention for Ostomy Self-Management Telehealth Intervention, Standard of care - Colorectal Cancer, Bladder Cancer | Phase 2 | Recruiting | City of Hope Medical Center | 150 | 2025-01-02 | 2026-03-05 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
Showing 20 of 35. Sign in to see all of them.
Urinary Bladder Neoplasms (35) · Ovarian Neoplasms (6) · Carcinoma, Transitional Cell (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Lung Neoplasms (4) · Melanoma (4) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4) · Stomach Neoplasms (4) · Breast Neoplasms (3) · Endometrial Neoplasms (3) · Esophageal Neoplasms (3) · Head and Neck Neoplasms (3) · Kidney Neoplasms (3)
Female Urogenital Diseases (35) · Female Urogenital Diseases and Pregnancy Complications (35) · Male Urogenital Diseases (35) · Neoplasms by Site (35) · Urinary Bladder Diseases (35) · Urogenital Diseases (35) · Urogenital Neoplasms (35) · Urologic Diseases (35) · Urologic Neoplasms (35) · Neoplasms (33) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (12) · Carcinoma (11) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8)
pembrolizumab (7) · enfortumab vedotin (5) · Cisplatin (4) · Gemcitabine (4) · Cystectomy (3) · Docetaxel (3) · Carboplatin (2) · Etoposide (2) · Clinical Trials, Phase II as Topic (1) · Cystoscopy (1) · Dutasteride (1) · Fluorodeoxyglucose F18 (1) · Immune Checkpoint Inhibitors (1) · Interleukin-15 (1) · Magnetic Resonance Spectroscopy (1)
Daiichi Sankyo (2) · Merck Sharp & Dohme LLC (2) · RenJi Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Changhai Hospital (1) · City of Hope Medical Center (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Essen Biotech (1) · Kyoto University Hospital (1) · Michael A. O'Donnell (1) · National Cancer Center, Korea (1) · National Cancer Institute (NCI) (1)
United States (19) · China (12) · France (4) · Netherlands (4) · Canada (3) · Italy (3) · Japan (3) · South Korea (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2) · Germany (2) · Israel (2)
Jean Hoffman-Censits, MD (2) · Abai Xu, doctor (1) · Alexander Z Wei, MD (1) · Bradley A McGregor, MD (1) · Charles Hsu, MD (1) · Esther Mena Gonzalez, M.D. (1) · Ho Kyung Seo, MD (1) · Jianjun Liu, Ph.D. & M.D. (1) · Mark Linch (1) · Michael A O'Donnell, MD (1) · Nestor Esnaola, M.D. (1) · Paul Crispen, MD (1) · Ricklie Julian, MD (1)
PMID 31752752, PMID 37871703, PMID 41088723, PMID 41469668, PMID 42142358
2025 (2), 2023 (1)